Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CG Oncology, Inc. - Common stock (NQ:CGON)

26.08 +1.13 (+4.53%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 Next >
Beyond The Numbers: 7 Analysts Discuss CG Oncology Stock
Via Benzinga
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
Via Investor Brand Network
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:REGN),(NASDAQ:VRTX),(OTCQX:RHHBY),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
3 Analysts Assess CG Oncology: What You Need To Know
Via Benzinga
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going
Issued on behalf of Oncolytics Biotech Inc. Vancouver, BC – June 18, 2025 – USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer.... 
Via FinancialNewsMedia
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
From CG Oncology Inc.
Via GlobeNewswire
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook
Via Benzinga
Which stocks are gapping on Monday?
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder cancer treatment at AUA 2025. 
Via Benzinga
These stocks are moving in today's pre-market session
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
Via Benzinga
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
The companies are working on treatments for a form of bladder cancer. 
Via Investor's Business Daily
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025
From CG Oncology Inc.
Via GlobeNewswire
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Friday's after hours session: top gainers and losers
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
Expert Outlook: CG Oncology Through The Eyes Of 4 Analysts
Via Benzinga
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
From CG Oncology Inc.
Via GlobeNewswire
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presented 
From CG Oncology Inc.
Via GlobeNewswire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.